J INTS BIO Unveils Promising Results for JIN-A02, a Fourth-Generation EGFR Inhibitor#South_Korea#Seoul#J_INTS_BIO#EGFR_Inhibitor#JIN-A02
J INTS BIO Unveils Promising Results for JIN-A02, a Fourth-Generation EGFR Inhibitor
J INTS BIO has revealed groundbreaking clinical research on JIN-A02, a fourth-generation EGFR inhibitor, offering new hope for patients with lung cancer.
third-news.com
February 12, 2026 at 7:06 AM
J INTS BIO Unveils Promising Results for JIN-A02, a Fourth-Generation EGFR Inhibitor#South_Korea#Seoul#J_INTS_BIO#EGFR_Inhibitor#JIN-A02
J INTS BIO Unveils Promising Clinical Results of JIN-A02 at ASCO 2025#South_Korea#Seoul#J_INTS_BIO#JIN-A02#EGFR-TKI
J INTS BIO Unveils Promising Clinical Results of JIN-A02 at ASCO 2025
J INTS BIO has shared interim findings from its clinical trial for JIN-A02, a fourth-generation EGFR-TKI, showing notable anti-tumor activity.
third-news.com
June 2, 2025 at 2:29 AM
J INTS BIO Unveils Promising Clinical Results of JIN-A02 at ASCO 2025#South_Korea#Seoul#J_INTS_BIO#JIN-A02#EGFR-TKI
Advancing Brain Tumor Treatments: J INTS BIO Unveils 'JIN-001' with MD Anderson#South_Korea#Seoul#J_INTS_BIO#MD_Anderson#JIN-001
Advancing Brain Tumor Treatments: J INTS BIO Unveils 'JIN-001' with MD Anderson
J INTS BIO and MD Anderson reveal outcomes from their collaboration on 'JIN-001,' a new therapy enhancing standard brain tumor treatments.
third-news.com
November 25, 2024 at 6:02 AM
Advancing Brain Tumor Treatments: J INTS BIO Unveils 'JIN-001' with MD Anderson#South_Korea#Seoul#J_INTS_BIO#MD_Anderson#JIN-001